Oncolytic viruses (OVs) have shown great anti-cancer potential in animal models, but only modest success in early clinical trials. A better understanding of the mechanisms underlining OV efficacy is needed to resolve this discrepancy. In the clinic, OV therapy will likely be combined with traditional chemotherapy, underscoring the need to also evaluate the interactions between these therapeutic modalities. Here we show that combining Sindbis viral vector therapy with the topoisomerase inhibitor irinotecan (CPT-11) results in the long-term survival of about 35% of SCID mice bearing aggressively growing ES2 human ovarian cancer. Single-agent treatments did not result in long-term survival. Flow cytometry analysis, bioluminescent imaging and survival experiments revealed that Sindbis and CPT-11 utilize non-overlapping natural killer (NK)-cell-dependent and -independent anti-cancer mechanisms, respectively. Notably, the combinatorial therapy was only effective in the presence of NK cells. These results highlight the hidden role of immune cell activation in combinatorial cancer therapy involving OVs and provide a potential method for tackling tumor cell resistance to cancer therapy while limiting treatment-related side effects.
All animal experiments were performed in accordance with NIH and institutional guidelines. In this study, we used 6--12-week-old female 'ES1/ SCID' mice from our own colony, which were generated by breeding C.B-17-SCID mice with Ces1c Foxn1/J mice (The Jackson Laboratory, Bar Harbor, ME), and were selected for the absence of T and B cells and for a deficiency in plasma esterase activity. CPT-11 can be cleaved into the more potent topoisomerase inhibitor SN-38 by mouse plasma esterase, of which there is no human homolog. Therefore, plasma esterase-deficient mice (ES1/SCID mice) more closely resemble the human condition for experiments utilizing CPT-11. 1 
Cell lines
Baby hamster kidney and human ovarian carcinoma (ES2) cells were obtained from the American Type Culture Collection. Baby hamster kidney cells were maintained in minimum essential a-modified media (aMEM, Mediatech) with 10% fetal calf serum. ES2 cells were cultured in McCoy's 5A medium (Mediatech, Herndon, VA, USA) supplemented with 10% fetal calf serum. All basal media were supplemented with 100 mg ml À1 of penicillin--streptomycin (Mediatech) and 0.5 mg ml À1 of amphotericin B (Mediatech).
ES2/Fluc cells were derived from the ES2 cell line by stable transfection of a plasmid, pIRES2-Fluc/EGFP, as previously described. 2 
Sindbis vector production
Sindbis vectors (Sin/LacZ and Sin/IL-12) were produced as previously described.
CPT-11 formulation
Irinotecan hydrochloride injection (CPT-11) was obtained from Teva Parenteral Medicines (Irvine, CA) and was diluted in phosphate-buffered saline (PBS) for mouse injections.
ES2 ovarian cancer model
Treatment started on day 4 or 5 after intraperitoneal inoculation of 1 Â 10 6 ES2/Fluc cells in 0.5 ml PBS. Sin/LacZ or Sin/IL-12 (B10 7 plaque-forming units in 0.5 ml of OptiMEM I) and mock treatments (0.5 ml of OptiMEM I) were administered intraperitoneally four times a week for 2 weeks, for a total of 8 treatments (Figures 1d and e) , or for 4 weeks, for a total of 16 treatments ( Figure 1a ). CPT-11 (15 mg kg À1 in 250 ml PBS for ES1/SCID mice and 10 mg kg À1 in 250 ml PBS for SCID and SCID/beige mice) was administered intraperitoneally on the same days that Sindbis was injected, 4--6 h after the Sindbis treatment. Therapeutic efficacy was monitored in two ways: tumor luminescence and survival. Noninvasive bioluminescent imaging was done using the IVIS Spectrum imaging system (Caliper Life Science, Hopkinton, MA, USA) and tumor growth was quantified using the Living Image 3.0 software (Caliper Life Science), as previously described. 2 Survival was monitored and recorded daily. In the SCID/beige experiment (n ¼ 60), two mice from different therapeutic groups died shortly after treatment was started and were excluded as outliers from the graph (Figure 1e ).
Flow cytometry (fluorescence-activated cell sorting) Anti-CD45 PE-Cy7 and anti-CD122 FITC antibodies were purchased from ebioscience, San Diego, CA. For analysis of peritoneal cells with fluorescence-activated cell sorting, mice were euthanized and their peritoneum was washed with 5 ml cold HBSS (Mediatech). Samples were then stained with the antibodies, washed twice with HBSS and analyzed using an LSR II machine (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo (Tree Star, Ashland, OR, USA). Immune cells were defined as CD45 þ cells and natural killer (NK) cells were defined as CD122 þ side scatter-low cells (not shown). We have previously used additional markers (NKp46 and NKG2D) to verify that these cells are indeed NK cells. NK cell quantification: peritoneal NK cells were quantified using the LSR II, by counting the NK cells in 0.5 ml of the original peritoneal 5-ml wash and multiplying this number by 10. Figure 1 . The role of NK cells in combinatorial therapy using Sindbis and CPT-11. (a) ES2-bearing ES1/SCID mice were treated with media, Sin/LacZ, CPT-11 or Sin/LacZ þ CPT-11, starting 5 days after tumor inoculation. Mice were treated four times a week for 4 weeks and survival was monitored daily. Sin/LacZ was injected in the morning and CPT-11 was injected on the same days in the afternoon. The effect of the treatment on mouse survival was monitored and plotted. The results of two independent experiments were combined (n ¼ 20). (b) Quantification of peritoneal NK cells in response to the therapy. ES2-bearing ES1/SCID mice were treated with mock, Sin/LacZ, CPT-11 or Sin/LacZ þ CPT-11 four times a week for 1 week. Mice were killed on day 2 and day 7 after treatment started and the peritoneal NK population of individual mice was determined using flow cytometry (n ¼ 3 for all groups except mock-treated mice on day 7, in which n ¼ 2). Each time point was taken from a separate independent experiment. Error bars represent s. -bearing ES1/SCID mice were treated intraperitoneally starting on day 4, four times a week, for 2 weeks, with media, Sin/LacZ, CPT-11 or Sin/LacZ þ CPT-11. NK cells were depleted using an anti-CD122 antibody, whereas control mice were treated with an isotype control antibody (n ¼ 4 for all groups). The effect of the treatment on tumor growth (luminescence) was monitored and quantified. Error bars represent s.e.m. (e) The experiment described in d was repeated using SCID and SCID/beige mice, and also using Sindbis vectors carrying the interleukin IL-12 (Sin/IL-12). Mouse survival was plotted and compared using Kaplan--Meier survival plots (n ¼ 4--5). NS, not significant (P40.05).
NK cell depletion NK cells were depleted using anti-CD122 (clone TM-b1; BioXcell, West Lebanon, NH). Antibodies were injected intraperitoneally starting 1 day before the first Sindbis treatment and were then injected every 2--3 days for 2 weeks. A total of 20 mg antibody in 0.2 ml PBS per mouse was used in the first injection and 10 mg antibody in 0.2 ml PBS was used in subsequent injections. Control groups were injected with a matched isotype control antibody.
Statistical analysis
Student's t-tests (two-tailed) and Kaplan--Meier log-rank test were done using Prism 4 for Macintosh (GraphPad Software, La Jolla, CA). Error bars shown represent the s.e.m. 3 In the clinical setting, OV therapy will likely be combined with chemotherapy. Two opposing strategies exist for combinatorial cancer therapy. One strategy is to attain synergism by having both drugs target the same mechanism. For example, immunosuppressive chemotherapy can be used to suppress the immune response to the OV, thereby increasing viral titers in vivo. Alternatively, the two therapies can be designed to target non-overlapping mechanisms. The advantage of this approach is the ability to target a heterogeneous tumor cell population in which individual tumor cells are resistant to one, but not both, of the therapies. This strategy also has the benefit of reducing possible side effects by using therapies with non-overlapping toxicities.
RESULTS AND DISCUSSION
Sindbis virus is an alphavirus with oncolytic properties that can inhibit tumor growth in various mouse models. 2 However, the precise mechanism of action of Sindbis therapy is still under investigation. We have recently shown that replication-defective Sindbis viral vectors can activate NK cells in a SCID mouse model of ovarian cancer. 4 Utilization of Sindbis vectors carrying the NK stimulator IL-12 prolonged survival, but was not able to cure tumor-bearing mice. In the current study, we combined Sindbis therapy (Sin/LacZ) with the topoisomerase inhibitor irinotecan (CPT-11), a clinically approved anti-cancer drug. We found that the combination therapy was significantly more effective than the single-agent treatments in SCID mice bearing intraperitoneally growing ES2 cells, an aggressively growing human ovarian cancer cell line (Figure 1a) .
Previous studies involving the combination of OVs and CPT-11 have focused on their function as a prodrug activation system. 5 However, the role of NK cells in these combinatorial therapies has not been investigated. Using flow cytometry, we found that Sindbis therapy, but not CPT-11, induced the influx of NK cells into the peritoneum of ES2-bearing mice (Figure 1b) . Side scatter analysis, which reflects cell granularity, revealed that peritoneal NK cells were activated in response to Sindbis therapy, but not CPT-11 (Figure 1c) . To determine the therapeutic significance of NK cell activation in our model, we depleted the NK cells in vivo using anti-CD122 antibodies, as described previously. 4 Tumor growth was monitored using luciferase-expressing ES2 cells, and mice were imaged using the IVIS imaging system. We found that Sindbis, but not CPT-11, required the presence of NK cells to achieve effective therapy (Figure 1d) . Similar results were obtained using anti-asialo GM1 antibody to deplete the NK cells (data not shown). These results were also confirmed using SCID/ beige mice, which lack functional NK cells (Figure 1e) . Notably, the combinatorial therapy was more effective than CPT-11 alone only in the presence of functional NK cells (Figures 1d  and e) , underscoring the role of these cells in the combinatorial effect. The NK-cell-independent anti-cancer mechanism of CPT-11 has been studied extensively and is believed to involve the induction of DNA damage and subsequent apoptosis, 6 though cell-cycle-independent CPT-11 toxicity has also been reported. 7 It should be noted, however, that the effects described in this study might be common to other combinations of OVs and chemotherapy. It is therefore worthwhile to consider the general potential interactions between chemotherapy and OV-activated NK cells.
Several factors make NK cells a good target for combinatorial therapies involving OVs. First, NK cells can be activated by viruses, but upon activation might also be able to target tumor cells. 4, 8 Second, NK cells have important regulatory functions, which could influence the generation of adaptive anti-tumor immunity. 8 Third, NK cells have a unique mode of action, which is distinct from the mode of action of conventional chemotherapies, and as a result, NK cell activation is not likely to overlap significantly with traditional chemotherapeutics. For example, slow-growing tumor cells that express NKG2D ligands may be susceptible to NK cell lysis, 9 whereas fast-growing tumor cells that lack NKG2D ligand expression may be susceptible to CPT-11 or other chemotherapeutics. In a heterogeneous tumor cell population, individual treatments may only have a limited effect, but together they might reach the threshold for effective therapy. Nevertheless, more complicated interactions between OV-activated NK cells and chemotherapy also need to be considered. For example, by reducing the size of the tumor, chemotherapy may also reduce the level of tumor-induced immunosuppression, therefore enabling a more effective NK cell response. Furthermore, smaller tumors or tumors compromised by chemotherapy may be more sensitive or accessible to NK cells. It may also be possible that chemotherapy enhances NK cell cytotoxicity directly, for example, by inducing the expression of NK-cell-activating stress ligands on tumor cells. Further research is needed to study these and other possible interactions between Sindbis therapy and CPT-11.
Finally, it is noteworthy to consider why in about 65% of the combinatorially treated mice, the tumors eventually regrew, leading to progressive disease and eventually death. One possible factor is that the mice simply did not have enough NK cells to tackle the growing cancer. We have previously shown that augmenting Sindbis therapy with syngeneic NK cells results in an enhanced therapeutic effect, 4 supporting this hypothesis. However, from a clinical point of view, NK cell injection into patients is a laborious procedure. Alternatively, it may be possible to augment NK cell activity in vivo by using Sindbis to deliver NK-cell-activating cytokines like IL-12 into the tumor environment. Indeed, our results demonstrate that combining Sindbis/IL-12 with CPT-11 results in an enhanced therapeutic effect (Figure 1e) .
One of the greatest challenges in cancer therapy is the emergence of therapy-resistant tumor cell subpopulations. Mechanisms of tumor resistance to the NK-cell-independent anti-cancer effects of CPT-11 have been reviewed previously. 10 Resistance to NK cell cytotoxicity can also develop, but may be overcome by using immunotherapies that activate multiple types of immune cells, and therefore utilize non-overlapping mechanisms to destroy the tumor cells. We have recently found that Sindbis/IL-12 induces the IFNg-dependent activation of peritoneal macrophages in ES2-bearing mice. 4 Further studies are needed to determine if IFNg-activated macrophages can target NK cell and CPT-11-resistant tumor cells in this model. In summary, based on our results, we believe that it is important to consider the role of NK and other immune cells in combinatorial therapies involving Sindbis or other OVs. We hope that this would lead to a better understanding of preclinical successes, and ultimately help us design rational and effective combinatorial therapies in the clinic.
